Nilotinib
Brand: Tasigna (US/EU) / Nilotinib (IN/BD)
Anticancer
BCR-ABL Tyrosine Kinase Inhibitor
Pharmacokinetics
| Half-life | 17 hours |
| Tmax | 3 h |
| Protein Binding | 98 % |
| Volume of Distribution | 0.6 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Must be taken on empty stomach. Food increases absorption → risk QT prolongation. |
⚠️ Safety & Warnings
Severity: Life-threatening
Adverse Effects:
QT prolongation, sudden death risk, hyperglycemia, hepatic toxicity
Contraindications:
QT prolongation history or uncorrected electrolytes
Precautions:
ECG before start; monitor QT; correct K/Mg before therapy